References
- Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008;372:139–144.
- Fast s. National Center for Health Statistics. Available from: http://www.cdc.gov/nchs/fastats
- Schug SA, Large RG. Economic considerations in pain management. Pharmacoeconomics. 1993;3:260–267.
- Owen H, McMillan V, Rogowski D. Postoperative pain therapy: a survey of patients’ expectations and their experiences. Pain. 1990;41:303–307.
- Warfield CA. Kahn CH. Acute pain management. Programs in U.S. hospitals and experiences and attitudes among U.S. adults. Anesthesiology. 1995;83:1090–1094.
- Babazade R, Turan A. Pharmacokinetic and pharmacodynamic evaluation of sublingual sufentanil in the treatment of post-operative pain. Expert Opin Drug Metab Toxicol. 2016;12:217–224.
- Skinner HB. Multimodal acute pain management. Am J Orthop (Belle Mead NJ). 2004;33:5–9.
- Subramanian P, Ramasamy S, Ng KH, et al. Pain experience and satisfaction with postoperative pain control among surgical patients. Int J Nurs Pract. 2016;22(3):232–238.
- Walder B, Schafer M, Henzi I, et al. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review. Acta Anaesthesiol Scand. 2001;45:795–804.
- Brian Meissner WN, Rodney (Rod) H, Sikirica V, et al. The rate and costs attributable to intravenous patient-controlled analgesia errors. Hosp Pharm. 2009;44:312–324.
- Palmer P, Ji X, Stephens J. Cost of opioid intravenous patient-controlled analgesia: results from a hospital database analysis and literature assessment. Clinicoecon Outcomes Res. 2014;6:311–318.
- Minkowitz HS, Candiotti K. The role of sublingual sufentanil nanotabs for pain relief. Expert Opin Drug Deliv. 2015;12:845–851.
- Vucković S, Prostran M, Ivanović M, et al. Fentanyl analogs: structure-activity-relationship study. Curr Med Chem. 2009;16:2468–2474.
- Roy SD, Flynn GL. Solubility and related physicochemical properties of narcotic analgesics. Pharm Res. 1988;5:580–586.
- de Lange S, Boscoe MJ, Stanley TH, et al. Comparison of sufentanil–O2 and fentanyl–02 for coronary artery surgery. Anesthesiology. 1982;56:112–118.
- Meuldermans WE, Hurkmans RM, Heykants JJ. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther. 1982;257:4–19.
- Ringold FG, Minkowitz HS, Gan TJ, et al. Sufentanil sublingual tablet system for the management of postoperative pain following open abdominal surgery: a randomized, placebo-controlled study. Reg Anesth Pain Med. 2015;40:22–30.
- Willsie SK, Evashenk MA, Hamel LG, et al. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. Clin Ther. 2015;37:145–155.
- Minkowitz HS, Singla NK, Evashenk MA, et al. Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. Reg Anesth Pain Med. 2013;38:131–139.
- Melson TI, Boyer DL, Minkowitz HS, et al. Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial. Pain Pract. 2014;14:679–688.
- Jove M, Griffin DW, Minkowitz HS, et al. Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty: a randomized, placebo-controlled study. Anesthesiology. 2015;123:434–443.
- Michiels M, Hendriks R, Heykants J. Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. J Pharm Pharmacol. 1983;35:86–93.
- Minkowitz HS. A review of sufentanil and the sufentanil sublingual tablet system for acute moderate to severe pain. Pain Manag. 2015;5:237–250.
- Niemegeers CJE, Schellekens KHL, Vanbever WFM, et al. Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs. Arzneimittel-Forschung/Drug Res. 1976;26:1551–1556.
- Weldon ST, Perry DF, Cork RC, et al. Detection of picogram levels of sufentanil by capillary gas chromatography. Anesthesiology. 1985;63:684–687.
- Meuldermans W, Woestenborghs R, Noorduin H, et al. Protein binding of the analgesics alfentanil and sufentanil in maternal and neonatal plasma. Eur J Clin Pharmacol. 1986;30:217–219.
- Mather LE. Opioids: a pharmacologist’s delight!. Clin Exp Pharmacol Physiol. 1995;22:833–836.
- Leysen JE, Gommeren W, Niemegeers CJE. [H-3]-labeled sufentanil, a superior ligand for mu-opiate receptors – binding-properties and regional distribution in rat-brain and spinal-cord. Eur J Pharmacol. 1983;87:209–225.
- Maciejewski D. Sufentanil in anaesthesiology and intensive therapy. Ther AI. 2012;44:35–41.
- Monk JP, Beresford R, Ward A. Sufentanil – a review of its pharmacological properties and therapeutic use. Drugs. 1988;36:286–313.
- Bovill JG, Sebel PS, Blackburn CL, et al. The pharmacokinetics of sufentanil in surgical patients. Anesthesiology. 1984;61:502–506.